{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:57:07Z","timestamp":1761562627777},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00384-020-03581-3","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T14:02:35Z","timestamp":1586959355000},"page":"1141-1148","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Infliximab levels and antibodies in IBD-related peripheral arthralgia"],"prefix":"10.1007","volume":"35","author":[{"given":"Asaf","family":"Levartovsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bella","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miri","family":"Yavzori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orit","family":"Picard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Eliakim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Roblin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"issue":"5","key":"3581_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00005792-197609000-00004","volume":"55","author":"AJ Greenstein","year":"1976","unstructured":"Greenstein AJ, Janowitz HD, Sachar DB (1976) The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine. 55(5):401\u2013412","journal-title":"Medicine."},{"issue":"4","key":"3581_CR2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/0016-5085(79)90391-3","volume":"77","author":"GB Rankin","year":"1979","unstructured":"Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr (1979) National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology. 77(4):914\u2013920","journal-title":"Gastroenterology."},{"issue":"10","key":"3581_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrgastro.2013.117","volume":"10","author":"C Ott","year":"2013","unstructured":"Ott C, Sch\u00f6lmerich J (2013) Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 10(10):585\u2013595","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"3581_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","volume":"23","author":"FT Veloso","year":"1996","unstructured":"Veloso FT, Carvalho J, Magro F (1996) Immune-related systemic manifestations of inflammatory bowel disease: a prospective study of 792 patients. J Clin Gastroenterol 23(1):29\u201334","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"3581_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","volume":"96","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P et al (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96(4):1116","journal-title":"Am J Gastroenterol"},{"issue":"9317","key":"3581_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317):1541\u20131549","journal-title":"Lancet"},{"issue":"9","key":"3581_CR7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer S (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350(9):876\u2013885","journal-title":"N Engl J Med"},{"issue":"23","key":"3581_CR8","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23):2462\u20132476","journal-title":"N Engl J Med"},{"issue":"1","key":"3581_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ibd.21663","volume":"18","author":"R L\u00f6fberg","year":"2012","unstructured":"L\u00f6fberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A, Pollack PF (2012) Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis 18(1):1\u20139","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"3581_CR10","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1097\/MIB.0000000000001109","volume":"23","author":"SR Vavricka","year":"2017","unstructured":"Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T, Swiss IBD Cohort Study Group (2017) Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study. Inflamm Bowel Dis 23(7):1174\u20131181","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"3581_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, Burisch J, de Vos M, de Vries AM, Dick AD, Juillerat P, Karlsen TH, Koutroubakis I, Lakatos PL, Orchard T, Papay P, Raine T, Reinshagen M, Thaci D, Tilg H, Carbonnel F, European Crohn\u2019s and Colitis Organisation (2016) The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohn's Colitis 10(3):239\u2013254","journal-title":"J Crohn's Colitis"},{"issue":"4","key":"3581_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","volume":"11","author":"S Ben-Horin","year":"2014","unstructured":"Ben-Horin S, Chowers Y (2014) Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 11(4):243\u2013255","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"3581_CR13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","volume":"11","author":"S Ben-Horin","year":"2013","unstructured":"Ben-Horin S, Waterman M, Kopylov U et al (2013) Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11(4):444\u2013447","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"3581_CR14","first-page":"549","volume":"11","author":"Y Davidov","year":"2016","unstructured":"Davidov Y, Ungar B, Bar-Yoseph H et al (2016) Association of induction infliximab levels with clinical response in perianal Crohn\u2019s disease. J Crohn's Colitis 11(5):549\u2013555","journal-title":"J Crohn's Colitis"},{"issue":"11","key":"3581_CR15","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1097\/MIB.0000000000001220","volume":"23","author":"S Fay","year":"2017","unstructured":"Fay S, Ungar B, Paul S et al (2017) The association between drug levels and endoscopic recurrence in postoperative patients with Crohn's disease treated with tumor necrosis factor inhibitors. Inflamm Bowel Dis 23(11):1924\u20131929","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"3581_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","volume":"14","author":"B Ungar","year":"2016","unstructured":"Ungar B, Levy I, Yavne Y et al (2016) Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 14(4):550\u2013557","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"3581_CR17","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","volume":"63","author":"B Ungar","year":"2014","unstructured":"Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, Kopylov U, Eliakim R, Ben-Horin S, ABIRISK consortium (2014) The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 63(8):1258\u20131264","journal-title":"Gut."},{"issue":"8167","key":"3581_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","volume":"315","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM (1980) A simple index of Crohn's-disease activity. Lancet 315(8167):514","journal-title":"Lancet"},{"issue":"4","key":"3581_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","volume":"8","author":"S Vermeire","year":"2010","unstructured":"Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P (2010) Correlation between the Crohn's disease activity and Harvey\u2013Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 8(4):357\u2013363","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"3581_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/gut.2004.056358","volume":"54","author":"PD Higgins","year":"2005","unstructured":"Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM (2005) Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 54(6):782\u2013788","journal-title":"Gut."},{"issue":"9","key":"3581_CR21","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/ibd.21919","volume":"18","author":"U Kopylov","year":"2011","unstructured":"Kopylov U, Mazor Y, Yavzori M, Fudim E, Katz L, Coscas D, Picard O, Chowers Y, Eliakim R, Ben-Horin S (2011) Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 18(9):1628\u20131633","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"3581_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/gut.2009.201533","volume":"60","author":"S Ben-Horin","year":"2011","unstructured":"Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, Coscas D, Bar-Meir S, Goldstein I, Chowers Y (2011) The immunogenic part of infliximab is the F (ab\u2032) 2 but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 60(1):41\u201348","journal-title":"Gut."},{"issue":"9","key":"3581_CR23","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/ibd\/izy065","volume":"24","author":"MC Dubinsky","year":"2018","unstructured":"Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Ganguli A, Wang A (2018) Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease. Inflamm Bowel Dis 24(9):1876\u20131882","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"3581_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/ajg.2012.363","volume":"108","author":"KS Nanda","year":"2013","unstructured":"Nanda KS, Cheifetz AS, Moss AC (2013) Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 108(1):40\u20137; quiz 48","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"3581_CR25","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.12869","volume":"40","author":"Y Mazor","year":"2014","unstructured":"Mazor Y, Almog R, Kopylov U, Ben Hur D, Blatt A, Dahan A, Waterman M, Ben-Horin S, Chowers Y (2014) Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 40(6):620\u2013628","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"3581_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, van Assche G, D' Haens G, Carbonez A, Rutgeerts P (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348(7):601\u2013608","journal-title":"N Engl J Med"},{"issue":"10","key":"3581_CR27","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","volume":"4","author":"EA Maser","year":"2006","unstructured":"Maser EA, Villela R, Silverberg MS, Greenberg GR (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease. Clin Gastroenterol Hepatol 4(10):1248\u20131254","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"3581_CR28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/ard.2004.021774","volume":"63","author":"H Peeters","year":"2004","unstructured":"Peeters H, Vander Cruyssen B, Laukens D, Coucke P, Marichal D, van den Berghe M, Cuvelier C, Remaut E, Mielants H, de Keyser F, Vos MD (2004) Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn\u2019s disease. Ann Rheum Dis 63(9):1131\u20131134","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3581_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0016-5085(00)70209-5","volume":"118","author":"TR Orchard","year":"2000","unstructured":"Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP (2000) Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 118(2):274\u2013278","journal-title":"Gastroenterology."},{"issue":"1","key":"3581_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","volume":"158","author":"A Sazonovs","year":"2020","unstructured":"Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, McDonald TJ (2020) HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease. Gastroenterology. 158(1):189\u2013199","journal-title":"Gastroenterology."},{"issue":"5","key":"3581_CR31","first-page":"631","volume":"11","author":"MC Karreman","year":"2017","unstructured":"Karreman MC, Luime JJ, Hazes JM, Weel AE (2017) The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. J Crohn's Colitis 11(5):631\u2013642","journal-title":"J Crohn's Colitis"},{"issue":"1","key":"3581_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0016-5085(94)90066-3","volume":"107","author":"S Bhagat","year":"1994","unstructured":"Bhagat S, Das KM (1994) A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology. 107(1):103\u2013108","journal-title":"Gastroenterology."},{"issue":"8","key":"3581_CR33","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka SR, Schoepfer A, Scharl M et al (2015) Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 21(8):1982\u20131992","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"3581_CR34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/ecco-jcc\/jjv159","volume":"9","author":"C Coutzac","year":"2015","unstructured":"Coutzac C, Chapuis J, Poullenot F, Chabrun E, Capdepont M, Blanco P, Laharie D (2015) Association between infliximab trough levels and the occurrence of paradoxical manifestations in patients with inflammatory bowel disease: a case-control study. J Crohn's Colitis 9(11):982\u2013987","journal-title":"J Crohn's Colitis"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-020-03581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-020-03581-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-020-03581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T08:12:34Z","timestamp":1618474354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-020-03581-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["3581"],"URL":"https:\/\/doi.org\/10.1007\/s00384-020-03581-3","relation":{},"ISSN":["0179-1958","1432-1262"],"issn-type":[{"value":"0179-1958","type":"print"},{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"4 April 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Bella Ungar: Consultation\/lecturer fees from Janssen, Takeda, Neopharm, and AbbVieRami Eliakim: Consultant and speaker fees from Janssen, AbbVie, Takeda, and MedtronicShomron Ben-Horin: Consulting and advisory board fees and\/or research support from AbbVie, MSD, Janssen, Takeda, and CellTrionUri Kopylov: Speaker and advisory fees from AbbVie, Janssen, MSD, Takeda, and Medtronic and research support from Janssen, Medtronic, and Takeda","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}